Physician profile
Vikas Dembla
NPI 1013128792
$568,142.55
in general payments reported to CMS, 2019-2025
62 companies · $37K in 2025
The $37K reported for 2025 was more than what 95% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $125K · 2020: $9,465 · 2021: $137K · 2022: $156K · 2023: $74K · 2024: $29K · 2025: $37K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $112K · Travel and Lodging: $13K · Food and Beverage: $7,731 · Consulting Fee: $7,266 · Education: $77.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $111,759.59 |
| Travel and Lodging | $13,419.60 |
| Food and Beverage | $7,730.71 |
| Consulting Fee | $7,266.00 |
| Education | $77.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $219,365.04 | 2019-2025 | Libtayo |
| Genzyme Corporation | $215,026.29 | 2019-2023 | |
| E.R. Squibb & Sons, L.L.C. | $69,645.99 | 2019-2025 | Opdivo, Opdualag |
| Mirati Therapeutics, INC. | $23,414.56 | 2023-2024 | Krazati |
| Astrazeneca Pharmaceuticals LP | $17,442.45 | 2019-2025 | Imfinzi, Lynparza, Tagrisso |
| Servier Pharmaceuticals LLC | $5,576.17 | 2021-2025 | |
| Genentech USA, INC. | $3,362.14 | 2019-2025 | Tecentriq, Columvi, Polivy |
| Celgene Corporation | $2,370.87 | 2019-2025 | Reblozyl, Pomalyst, Opdualag |
| Taiho Oncology, INC. | $1,677.69 | 2020-2025 | |
| Ipsen Biopharmaceuticals, INC | $1,470.18 | 2019-2024 | Onivyde, Somatuline Depot, Tazverik |
| Bayer Healthcare Pharmaceuticals INC. | $948.24 | 2020-2022 | |
| Eisai INC. | $877.90 | 2021-2025 | |
| Abbvie INC. | $756.62 | 2022-2025 | Venclexta |
| Merck Sharp & Dohme LLC | $686.43 | 2019-2025 | Keytruda, Welireg, Lynparza |
| Janssen Biotech, INC. | $581.17 | 2019-2025 | Darzalex, Imbruvica, Tecvayli |
Show all 61 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $494.49 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $494.35 | 2019-2025 | |
| Incyte Corporation | $441.60 | 2019-2025 | Monjuvi, Pemazyre, Jakafi |
| Daiichi Sankyo INC. | $308.56 | 2019-2025 | Enhertu, Injectafer, Datroway |
| Takeda Pharmaceuticals U.S.A., INC. | $284.02 | 2021-2024 | Iclusig, Fruzaqla |
| Amgen INC. | $249.18 | 2019-2025 | Kyprolis, Blincyto, Lumakras |
| Pharmacyclics LLC, An Abbvie Company | $240.69 | 2020-2023 | Imbruvica, Epkinly |
| Glaxosmithkline, LLC. | $211.21 | 2021-2025 | Ojjaara, Blenrep, Zejula |
| Astellas Pharma US INC | $189.68 | 2019-2021 | |
| Lilly USA, LLC | $152.61 | 2019-2025 | Jaypirca, Retevmo, Verzenio |
| Seagen INC. | $148.45 | 2022-2023 | Adcetris, Tukysa |
| Beigene USA, INC. | $146.58 | 2023-2025 | Brukinsa, Tevimbra |
| Array Biopharma INC | $137.86 | 2022-2025 | Braftovi, Mektovi, Lorbrena |
| Boehringer Ingelheim Pharmaceuticals, INC. | $117.12 | 2021-2025 | |
| Exelixis INC. | $116.74 | 2022-2025 | Cabometyx |
| Monteris Medical Corporation | $116.29 | 2024 | Neuroblate |
| Karyopharm Therapeutics INC. | $112.80 | 2022-2024 | Xpovio |
| Rigel Pharmaceuticals, INC. | $80.85 | 2021-2024 | Tavalisse, Rezlidhia |
| Gilead Sciences, INC. | $75.94 | 2023-2024 | Trodelvy |
| Advanced Accelerator Applications | $60.68 | 2019 | |
| Beone Medicines USA, INC. | $60.17 | 2025 | Brukinsa |
| Kite Pharma, INC. | $55.19 | 2023 | Yescarta |
| Alexion Pharmaceuticals, INC. | $52.30 | 2021-2022 | |
| Sirtex Medical INC | $50.82 | 2019-2020 | |
| Deciphera Pharmaceuticals INC. | $47.98 | 2024-2025 | Qinlock, Romvimza |
| Epizyme, INC. | $46.54 | 2022 | |
| Coherus Oncology, INC. | $40.85 | 2021 | |
| Sobi, INC | $35.59 | 2025 | |
| Springworks Therapeutics, INC. | $33.88 | 2025 | Ogsiveo, Gomekli |
| Emd Serono, INC. | $29.95 | 2023 | Tepmetko |
| Kyowa Kirin, INC. | $27.45 | 2019-2023 | Poteligeo |
| Stemline Therapeutics INC. | $25.93 | 2025 | Orserdu |
| Lexicon Pharmaceuticals, INC. | $24.69 | 2019-2020 | |
| Clovis Oncology, INC. | $24.40 | 2019-2020 | |
| Immunogen, INC. | $22.53 | 2023 | Elahere |
| Morphosys, US INC. | $22.39 | 2021 | |
| Tg Therapeutics, INC. | $20.90 | 2021 | |
| Tempus Ai, INC | $19.32 | 2025 | Xt Cdx |
| Aveo Pharmaceuticals, INC. | $19.06 | 2024 | |
| Syndax Pharmaceuticals, INC. | $19.06 | 2025 | |
| Pharmaessentia USA Corporation | $17.47 | 2025 | Besremi |
| Adc Therapeutics America, INC. | $15.23 | 2025 | |
| Tersera Therapeutics LLC | $14.43 | 2021 | |
| Puma Biotechnology, INC. | $12.54 | 2019 | |
| Amag Pharmaceuticals, INC. | $12.06 | 2019 | |
| Secura Bio, INC. | $10.38 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vikas Dembla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.